Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

by · The Cerbat Gem

Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) was the target of a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 3,783 shares, a drop of 60.7% from the April 15th total of 9,626 shares. Based on an average trading volume of 5,552 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.0% of the company’s shares are short sold.

Bavarian Nordic Stock Down 1.3%

Shares of BVNRY traded down $0.13 during midday trading on Thursday, reaching $9.69. The company had a trading volume of 2,161 shares, compared to its average volume of 3,505. Bavarian Nordic has a 1-year low of $8.11 and a 1-year high of $13.00. The stock has a market cap of $2.30 billion, a PE ratio of 11.01 and a beta of 1.21. The firm has a 50 day simple moving average of $9.85 and a 200-day simple moving average of $10.08.

Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $165.70 million during the quarter. Bavarian Nordic had a net margin of 22.20% and a return on equity of 11.27%.

About Bavarian Nordic

(Get Free Report)

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

Featured Stories